Christein John D, Hollinger Edward F, Millikan Keith W
Department of General Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA.
Am Surg. 2002 Mar;68(3):258-62; discussion 262-3.
A retrospective review of esophagectomy for esophageal carcinoma between 1982 and 1999 was performed. Two hundred twenty-two patients (mean age 61.7 years) underwent esophagectomy: 128 transhiatal, 74 Ivor Lewis, and 20 abdominal. Most tumors were adenocarcinoma (65%); the majority were in the lower third or cardia (78%). Excluding operative mortality the one-, 3-, and 5-year survival rates were 67, 39, and 31 per cent (median survival, 16.3 months) respectively. The hospital mortality rate was 6.8 per cent. Through univariate analysis race other than white, history of weight loss, poor or moderate differentiation (P = 0.05), full-thickness invasion (P = 0.02), positive lymph nodes (P < 0.01), Ivor Lewis esophagectomy (P = 0.02), intraoperative blood transfusion (P = 0.01), and tumor location in the upper or middle third in node-positive patients (P = 0.02) were associated with a poorer survival. Adjuvant therapy improved survival for patients with positive lymph nodes (P < 0.01). In multivariate analysis positive lymph nodes, tumor location, intraoperative blood transfusion, and adjuvant therapy were independent predictors of survival. To optimize survival esophagectomy for esophageal carcinoma should be performed without blood transfusion, and node-positive patients should receive multimodal therapy.
对1982年至1999年间食管癌食管切除术进行了回顾性研究。222例患者(平均年龄61.7岁)接受了食管切除术:128例经裂孔,74例采用艾弗·刘易斯术式,20例采用腹部手术。大多数肿瘤为腺癌(65%);大多数位于食管下三分之一或贲门部(78%)。排除手术死亡率后,1年、3年和5年生存率分别为67%、39%和31%(中位生存期16.3个月)。医院死亡率为6.8%。通过单因素分析,非白人种族、体重减轻史、低分化或中分化(P = 0.05)、全层浸润(P = 0.02)、淋巴结阳性(P < 0.01)、艾弗·刘易斯食管切除术(P = 0.02)、术中输血(P = 0.01)以及淋巴结阳性患者肿瘤位于食管上三分之一或中三分之一(P = 0.02)与较差的生存率相关。辅助治疗可提高淋巴结阳性患者的生存率(P < 0.01)。多因素分析显示,淋巴结阳性、肿瘤位置、术中输血和辅助治疗是生存的独立预测因素。为优化生存率,食管癌食管切除术应避免输血,淋巴结阳性患者应接受多模式治疗。